Bio-Techne Executive and Leadership Team

James Hippel, the Executive Vice President & Chief Financial Officer at Bio-Techne, manages the global financial strategy, capital structure, and investor relations for the organization. Hippel oversees the fiscal planning required to sustain long-term growth in the competitive life sciences market, ensuring that investment in R&D remains a top priority. By directing financial reporting and risk management, the Executive Vice President & Chief Financial Officer provides the transparency and stability needed to support the company's expansion into new diagnostic territories. James Hippel also collaborates with the Board to evaluate potential acquisitions and strategic partnerships that enhance the product portfolio. Through the rigorous analysis of market trends and financial performance, the Executive Vice President & Chief Financial Officer optimizes the allocation of resources across all business segments. Hippel secures the financial foundation of the company, enabling the continued delivery of high-quality reagents and diagnostic tools to the global research community.

Steve Crouse, the President, Diagnostics & Spatial Biology Segment at Bio-Techne, leads the commercialization and strategic growth of the company's diagnostic and spatial biology product lines. Crouse oversees the development of high-precision tools that enable researchers to map biological processes with unprecedented accuracy. By driving the expansion of these segments into global clinical markets, the President, Diagnostics & Spatial Biology Segment ensures that the company provides the means for accurate disease diagnosis and monitoring. Steve Crouse also manages the integration of new spatial biology technologies into the existing diagnostic portfolio, creating a comprehensive suite of solutions for the research community. Through the strategic alignment of product development with clinical needs, the President, Diagnostics & Spatial Biology Segment accelerates the adoption of advanced diagnostic methods. Crouse maintains a focus on market penetration and customer success, ensuring that these specialized tools deliver measurable value in the fight against complex diseases.

Will Geist, the President, Protein Sciences Segment at Bio-Techne, directs the research, production, and distribution of the company's core portfolio of bioactive reagents and proteins. Geist oversees the operational scale of the protein sciences division, ensuring that the supply of high-quality reagents meets the rigorous demands of global drug discovery efforts. By driving innovation in protein engineering and manufacturing, the President, Protein Sciences Segment enables scientific investigations into the fundamental nature of biological processes. Will Geist also manages the strategic partnerships that facilitate the integration of these reagents into broader clinical diagnostic workflows. Through the optimization of production processes and the expansion of the product catalog, the President, Protein Sciences Segment supports the company's mission to provide essential tools for the research community. Geist ensures that the protein sciences segment remains a cornerstone of the organization, delivering the consistency and reliability required for breakthrough scientific discoveries.

Laurie Gilman, the Vice President, Finance Operations & Chief of Staff at Bio-Techne, directs the integration of financial workflows with executive decision-making processes. Gilman manages the operational efficiency of internal fiscal systems, ensuring that resource allocation aligns with the broader research and diagnostic goals of the organization. By streamlining cross-departmental communication, the Vice President, Finance Operations & Chief of Staff facilitates rapid response times to shifting market demands in the life sciences sector. Laurie Gilman also coordinates high-level strategic initiatives that support the company's global footprint, particularly regarding the scaling of financial infrastructure across international markets. Through rigorous oversight of budgetary compliance and operational performance metrics, the Vice President, Finance Operations & Chief of Staff maintains the fiscal health necessary for sustained innovation. This leadership role bridges the gap between complex financial data and actionable business intelligence, ultimately driving the long-term stability of the enterprise.

Gary Latham, the Vice President & Chief Technology Officer at Bio-Techne, architects the technological roadmap for the development of innovative bioactive reagents and research tools. Latham oversees the integration of cutting-edge scientific platforms, ensuring that the company remains at the forefront of biological process investigation. By driving R&D initiatives, the Vice President & Chief Technology Officer enables the creation of high-precision instruments essential for drug discovery efforts. Gary Latham also manages the technical collaboration between internal research teams and external clinical diagnostic partners to expand the reach of proprietary technologies across North American and European markets. Through the implementation of advanced analytical systems, the Vice President & Chief Technology Officer optimizes product development cycles, directly impacting the speed at which new diagnostic solutions reach the market. Latham secures the competitive advantage of the organization by fostering a culture of continuous technical advancement and scientific excellence.

Cheryl Bethune, the Senior Vice President - Chief Human Resources Officer at Bio-Techne, drives the talent acquisition and organizational development strategies necessary to support a global life sciences workforce. Bethune designs comprehensive programs for employee engagement, leadership development, and performance management, ensuring that the company attracts top-tier scientific and operational talent. By aligning human capital initiatives with the overarching business mission, the Senior Vice President - Chief Human Resources Officer fosters an environment conducive to high-impact research and diagnostic innovation. Cheryl Bethune also oversees the implementation of corporate culture policies across diverse international regions, maintaining consistency in professional standards and operational excellence. Through the strategic management of organizational structure and workforce planning, the Senior Vice President - Chief Human Resources Officer supports the scalability of the business. Bethune ensures that the human element of the company remains robust, agile, and fully equipped to meet the evolving challenges of the global clinical diagnostic community.

Matt Mehlbrech, the IT Chief Information Officer & Vice President at Bio-Techne, directs the digital transformation and information security strategies that underpin the company's global operations. Mehlbrech manages the complex IT infrastructure required to support high-throughput research data, clinical diagnostic systems, and secure supply chain logistics. By implementing scalable cloud solutions and advanced data analytics, the IT Chief Information Officer & Vice President ensures that scientific teams have reliable access to the information necessary for drug discovery. Matt Mehlbrech also oversees the protection of intellectual property and sensitive clinical data, maintaining compliance with international regulatory standards. Through the modernization of internal systems, the IT Chief Information Officer & Vice President drives operational efficiency and cross-functional collaboration across all business units. Mehlbrech ensures that the technological backbone of the organization remains resilient, secure, and capable of supporting the rapid pace of innovation within the life sciences industry.